How we treat management of warfarin-associated coagulopathy in patients with intracerebral hemorrhage.

Link to article at PubMed

How we treat management of warfarin-associated coagulopathy in patients with intracerebral hemorrhage.

Blood. 2011 Mar 16;

Authors: Goodnough LT, Shander A

Intracerebral hemorrhage (ICH) in patients with warfarin-associated coagulopathy is an increasingly common life-threatening condition that requires emergent management. The evolution of therapeutic options in this setting, as well as recently published guidelines, have resulted in some heterogeneity in recommendations by professional societies. This heterogeneity can be attributed to: lack of evidence-based support for plasma therapy; the variability in availability of prothrombin complex concentrates (PCCs); the variability in the coagulation factor levels and contents of PCCs; ambiguity regarding the optimal dose and route of administration of Vitamin K; and the lack of standardized clinical care pathways, particularly in community hospitals, for the management of these critical care patients. In this review, we summarize the relevant literature regarding these controversies, and present suggestions for management of patients with warfarin-associated coagulopathy and ICH.

PMID: 21411756 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *